NEW YORK (GenomeWeb) – Meridian Bioscience issued preliminary fiscal year 2017 earnings before the opening of the market today, reporting a 2 percent year-over-year increase in revenues.
Meridian expects revenues of $200.5 million for its fiscal year ending Sept. 30, 2017, including fourth quarter revenues of $49.5 million. Non-GAAP earnings per share should be in the $.66 to $.67 range for the year, according to the firm.